ASLAN Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia-prevalent tumour types, and JHL Biotech, Asia’s premiere provider of bespoke biologics contract manufacturing services, have announced a manufacturing services partnership under which JHL will provide process development services to ASLAN for the continued development of its ASLAN004 programme
Under the partnership, ASLAN will work with JHL to perform process development and manufacturing of ASLAN004, a fully human monoclonal antibody that blocks the signalling of the IL-4 and IL-13 receptors.
The agreement will see ASLAN’s team work closely with JHL on analytics and process development for the manufacture of ASLAN004 for clinical trials. Development and manufacturing of ASLAN004 will commence in 2016 and will be undertaken at JHL Biotech’s GMP-certified facility in Zhubei, Taiwan.
Mark McHale, Chief Operating Officer, ASLAN Pharmaceuticals, said: “ASLAN is pleased to be working with a high quality partner such as JHL, whose capabilities in process development and manufacturing will enable us to accelerate the development of our unique and proprietary biologics pipeline. Working with JHL enables ASLAN to broaden our strategic partnerships with key partners in the region as we remain focused on developing novel therapies to address Asia-prevalent cancers.”
“We are excited to announce our CMC partnership with ASLAN. ASLAN is a world-class pharmaceutical company dedicated to making innovative therapies that cure Asia-specific diseases. JHL exists to make world-class medicines affordable to all, with a focus on broadening access to life-saving therapies in Asia," said Racho Jordanov, Chief Executive Officer of JHL Biotech.
"As such, this CMC partnership is a perfect match of ASLAN’s research and JHL’s development capabilities. We believe our collaboration on ASLAN004 will accelerate testing of this potential life-saving therapy, and we look forward to working with a team we admire and respect,” he added.